ClinicalTrialsFinder
RecruitingNot ApplicableNCT05940272

Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers

Evaluation of a Communication Intervention (Hematolo-GIST) for Large B-Cell Lymphoma Providers

Sponsor

Memorial Sloan Kettering Cancer Center

Enrollment

48 participants

Start Date

Jul 3, 2023

Study Type

INTERVENTIONAL

Conditions

DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoma, B-CellLarge B-cell LymphomaLarge-cell LymphomaMediastinal B-Cell Diffuse Large Cell Lymphoma

Summary

The purpose of this study is to develop and test a new communication training intervention called Hematolo-GIST to help oncologists communicate with patients about their lymphoma diagnosis and advance care planning.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is training oncology providers in communication skills to help them have more effective and compassionate conversations with patients who have large B-cell lymphoma (an aggressive blood cancer), particularly around prognosis and treatment decisions. **You may be eligible if...** - You are a healthcare provider (doctor, nurse, etc.) at Memorial Sloan Kettering who cares for patients with diffuse large B-cell lymphoma (DLBCL) or similar lymphoma types - Or you are a patient at the same institution who has been diagnosed with DLBCL and are available for feedback sessions **You may NOT be eligible if...** - You are a provider who does not treat DLBCL patients - You are a patient who does not have a confirmed DLBCL diagnosis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BEHAVIORALHematolo-GIST Training

Hematologist will participate in a group Hematolo-GIST training provided remotely via the study team.

BEHAVIORALParticipants Appointment

Participants will meet with Hematolo-GIST trained hematologists. Participants will consent to having their appointment audio-recorded on password-protected devices or MSK approved secure platforms.

Locations(2)

Memorial Sloan Kettering Cancer Center (All protocol activities)

New York, New York, United States

NEW YORK PRESBYTERIAN HOSPITAL (Data Collection Only)

New York, New York, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05940272

Related Trials

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy

NCT052379863 locations

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

NCT032585671 location

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

NCT047398131 location

Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma

NCT073160101 location

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

NCT073023473 locations